Editorial
J-ALEX trial will crown alectinib as the standard choice for anaplastic lymphoma kinase positive untreated non-small cell lung cancer patients?
Abstract
About 4–5% of advanced non-small cell lung cancer (NSCLC) patients are diagnosed with an oncogene- addicted disease, due to the presence of echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion gene (1). Before August 2011, chemotherapy was the only option for those patients.
